Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics

Anemia

Volumn 2012, Issue , 2012, Pages

  Jenkins, Chelsea ^a   Kan, Jenny ^a   Hoatlin, Maureen E ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873824707     PISSN: 20901267     EISSN: 20901275     Source Type: Journal    
DOI: 10.1155/2012/481583     Document Type: Review

References (75)

1. Wang W., Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nature Reviews Genetics 2007 8 10 735 748 2-s2.0-34548759123 10.1038/nrg2159 (Pubitemid 47429206)
2. de Winter J. P., Joenje H., The genetic and molecular basis of Fanconi anemia. Mutation Research 2009 668 1-2 11 19 2-s2.0-67650500593 10.1016/j.mrfmmm.2008.11.004
3. Takata H., Tanaka Y., Matsuura A., Late S phase-specific recruitment of Mre11 complex triggers hierarchical assembly of telomere replication proteins in Saccharomyces cerevisiae. Molecular Cell 2005 17 4 573 583 2-s2.0-13944265075 10.1016/j.molcel.2005.01.014 (Pubitemid 40269121)
4. Yan Z., Delannoy M., Ling C., Daee D., Osman F., Muniandy P. A., Shen X., Oostra A. B., Du H., Steltenpool J., Lin T., Schuster B., Décaillet C., Stasiak A., Stasiak A. Z., Stone S., Hoatlin M. E., Schindler D., Woodcock C. L., Joenje H., Sen R., de Winter J. P., Li L., Seidman M. M., Whitby M. C., Myung K., Constantinou A., Wang W., A histone-fold complex and FANCM forma conserved DNA-remodeling complex to maintain genome stability. Molecular Cell 2010 37 6 865 878 2-s2.0-77949701960 10.1016/j.molcel.2010.01.039
5. Kitao H., Takata M., Fanconi anemia: a disorder defective in the DNA damage response. International Journal of Hematology 2011 93 4 417 424 2-s2.0-79955942240 10.1007/s12185-011-0777-z
6. Rosado I.V., Langevin F., Crossan G. P., Formaldehyde catabolism is essential in cells deficient for the Fanconi anemia DNA-repair pathway. Nature Structural & Molecular Biology 2011 18 12 1432 1434
7. Ciccia A., Ling C., Coulthard R., Yan Z., Xue Y., Meetei A. R., Laghmani E. H., Joenje H., McDonald N., de Winter J. P., Wang W., West S. C., Identification of FAAP24, a Fanconi Anemia core complex protein that interacts with FANCM. Molecular Cell 2007 25 3 331 343 2-s2.0-33846799430 10.1016/j.molcel.2007.01.003 (Pubitemid 46206138)
8. Ling C., Ishiai M., Ali A. M., Medhurst A. L., Neveling K., Kalb R., Yan Z., Xue Y., Oostra A. B., Auerbach A. D., Hoatlin M. E., Schindler D., Joenje H., De Winter J. P., Takata M., Meetei A. R., Wang W., FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO Journal 2007 26 8 2104 2114 2-s2.0-34247208998 10.1038/sj.emboj.7601666 (Pubitemid 46625801)
9. Ali A. M., Singh P. A., Singh T. R., Du C., Li J., Wahengbam K., Grassman E., Auerbach AD, Pang Q., FAAP20: a novel ubiquitin-binding FA nuclear core complex protein required for functional integrity of the FA-BRCA DNA repair pathway. Blood 2012 119 14 3285 3294
10. Kim H., Yang K., Dejsuphong D., D'Andrea A. D., Regulation of Rev1 by the Fanconi anemia core complex. Nature Structural and Molecular Biology 2012 19 2 164 170
11. Shimamura A., De Oca R. M., Svenson J. L., Haining N., Moreau L. A., Nathan D. G., D'Andrea A. D., A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 2002 100 13 4649 4654 2-s2.0-0037114696 10.1182/blood-2002-05-1399 (Pubitemid 35429710)
12. Yang K., Moldovan G. L., Vinciguerra P., Murai J., Takeda S., D'Andrea A. D., Regulation of the Fanconi anemia pathway by a SUMO-like delivery network. Genes and Development 2011 25 17 1847 1858
13. Smogorzewska A., Desetty R., Saito T. T., Schlabach M., Lach F. P., Sowa M. E., Clark A. B., Kunkel T. A., Harper J. W., Colaiácovo M. P., Elledge S. J., A Genetic screen identifies FAN1, a Fanconi Anemia-associated nuclease necessary for DNA interstrand crosslink repair. Molecular Cell 2010 39 1 36 47 2-s2.0-77954286076 10.1016/j.molcel.2010.06.023
14. MacKay C., Déclais A. C., Lundin C., Agostinho A., Deans A. J., MacArtney T. J., Hofmann K., Gartner A., West S. C., Helleday T., Lilley D. M. J., Rouse J., Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell 2010 142 1 65 76 2-s2.0-77954274685 10.1016/j.cell.2010.06.021
15. Liu T., Ghosal G., Yuan J., Chen J., Huang J., FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science 2010 329 5992 693 696 2-s2.0-77955290719 10.1126/science.1192656
16. Kratz K., Schöpf B., Kaden S., Sendoel A., Eberhard R., Lademann C., Cannavó E., Sartori A. A., Hengartner M. O., Jiricny J., Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. Cell 2010 142 1 77 88 2-s2.0-77954279611 10.1016/j.cell.2010.06.022
17. Shereda R. D., Machida Y., Machida Y. J., Human KIAA1018/FAN1 localizes to stalled replication forks via its ubiquitin-binding domain. Cell Cycle 2010 9 19 3977 3983 2-s2.0-77958473038 10.4161/cc.9.19.13207
18. Jung Y., Lippard S. J., Direct cellular responses to platinum-induced DNA damage. Chemical Reviews 2007 107 5 1387 1407 2-s2.0-34249900982 10.1021/cr068207j (Pubitemid 46864967)
19. Chirnomas D., Taniguchi T., De La Vega M., Vaidya A. P., Vasserman M., Hartman A. R., Kennedy R., Foster R., Mahoney J., Seiden M. V., D'Andrea A. D., Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Molecular Cancer Therapeutics 2006 5 4 952 961 2-s2.0-33646582299 10.1158/1535-7163.MCT-05-0493 (Pubitemid 43724595)
20. Helleday T., Petermann E., Lundin C., Hodgson B., Sharma R. A., DNA repair pathways as targets for cancer therapy. Nature Reviews Cancer 2008 8 3 193 204 2-s2.0-39749166975 10.1038/nrc2342 (Pubitemid 351301852)
21. Taniguchi T., Tischkowitz M., Ameziane N., Hodgson S. V., Mathew C. G., Joenje H., Mok S. C., D'Andrea A. D., Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Medicine 2003 9 5 568 574 2-s2.0-0038075462 10.1038/nm852 (Pubitemid 36597103)
22. Landais I., Sobeck A., Stone S., LaChapelle A., LaChapelle A., Autier P., Autier P., A novel cell-free screen identifies a potent inhibitor of the fanconi anemia pathway. International Journal of Cancer 2009 124 4 783 792 2-s2.0-58149457080 10.1002/ijc.24039
23. Rai R., Peng G., Li K., Lin S. Y., DNA damage response: the players, the network and the role in tumor suppression. Cancer Genomics and Proteomics 2007 4 2 99 106 2-s2.0-34247398807 (Pubitemid 46632031)
24. Fong P. C., Boss D. S., Yap T. A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M. J., Ashworth A., Carmichael J., Kaye S. B., Schellens J. H. M., De Bono J. S., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New England Journal of Medicine 2009 361 2 123 134 2-s2.0-67650471685 10.1056/NEJMoa0900212
25. Helleday T., Bryant H. E., Schultz N., Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 2005 4 9 1176 1178 2-s2.0-25444471892 (Pubitemid 41365386)
26. Lord C. J., McDonald S., Swift S., Turner N. C., Ashworth A., A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair 2008 7 12 2010 2019 2-s2.0-55149105872 10.1016/j.dnarep.2008.08.014
27. Weil M. K., Chen A. P., PARP inhibitor treatment in ovarian and breast cancer. Current Problems in Cancer 2011 35 1 7 50 2-s2.0-79551587725 10.1016/j.currproblcancer.2010.12.002
28. Dedes K. J., Wilkerson P. M., Wetterskog D., Weigelt B., Ashworth A., Reis-Filho J. S., Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle 2011 10 8 1192 1199 2-s2.0-79954560252 10.4161/cc.10.8.15273
29. Wysham W. Z., Mhawech-Fauceglia P., Li H., BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One 2012 7 1, article e30042
30. Kaye S. B., Lubinski J., Matulonis U., Ang J. E., Gourley C., Karlan B. Y., Amnon A., Bell-McGuinn K. M., Chen L. M., Friedlander M., Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of Clinical Oncology 2012 30 4 372 379
31. Sessa C., Update on PARP1 inhibitors in ovarian cancer. Annals of Oncology 2011 22 supplement 8 viii72 viii76
32. Guha M., PARP inhibitors stumble in breast cancer. Nature Biotechnology 2011 29 5 373 374
33. Weston V. J., Oldreive C. E., Skowronska A., Oscier D. G., Pratt G., Dyer M. J. S., Smith G., Powell J. E., Rudzki Z., Kearns P., Moss P. A. H., Taylor A. M. R., Stankovic T., The PARP inhibitor olaparib induces significant killing of ATM-deficientlymphoid tumor cells in vitro and in vivo. Blood 2010 116 22 4578 4587 2-s2.0-78649321855 10.1182/blood-2010-01-265769
34. Senra J. M., Telfer B. A., Cherry K. E., McCrudden C. M., Hirst D. G., O'Connor M. J., Wedge S. R., Stratford I. J., Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Molecular Cancer Therapeutics 2011 10 10 1949 1958
35. van Vuurden D. G., Hulleman E., Meijer O. L. M., PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget 2011 2 12 984 996
36. Fraser M., Zhao H., Luoto K. R., Lundin C, Coackley C, Chan N, Joshua AM, Bismar TA, Evans A, Helleday T, Bristow R. G., PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clinical Cancer Research 2012 18 4 1015 1027
37. Pichierri P., Averbeck D., Rosselli F., DNA cross-link-dependent RAD50/MRE11/NBS1 subnuclear assembly requires the Fanconi anemia C protein. Human Molecular Genetics 2002 11 21 2531 2546 2-s2.0-0036796260 (Pubitemid 35174684)
38. Mendes-Pereira A. M., Martin S. A., Brough R., McCarthy A., Taylor J. R., Kim J. S., Waldman T., Lord C. J., Ashworth A., Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Molecular Medicine 2009 1 6-7 315 322 2-s2.0-77149157867 10.1002/emmm.200900041
39. Salmena L., Carracedo A., Pandolfi P. P., Tenets of PTEN tumor suppression. Cell 2008 133 3 403 414 2-s2.0-43049128529 10.1016/j.cell.2008.04. 013 (Pubitemid 351622014)
40. Shen W. H., Balajee A. S., Wang J., Wu H., Eng C., Pandolfi P. P., Yin Y., Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007 128 1 157 170 2-s2.0-33845999615 10.1016/j.cell.2006.11.042 (Pubitemid 46048887)
41. Mutter G. L., Lin M. C., Fitzgerald J. T., Kum J. B., Baak J. P. A., Lees J. A., Weng L. P., Eng C., Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. Journal of the National Cancer Institute 2000 92 11 924 931 2-s2.0-0034616634 (Pubitemid 30429193)
42. Marsit C. J., Zheng S., Aldape K., Hinds P. W., Nelson H. H., Wiencke J. K., Kelsey K. T., PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Human Pathology 2005 36 7 768 776 2-s2.0-23444461754 10.1016/j.humpath.2005.05. 006 (Pubitemid 41112032)
43. Paez J. G., Jänne P. A., Lee J. C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F. J., Lindeman N., Boggon T. J., Naoki K., Sasaki H., Fujii Y., Eck M. J., Sellers W. R., Johnson B. E., Meyerson M., EGFR mutations in lung, cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 5676 1497 1500 2-s2.0-2342624080 10.1126/science.1099314 (Pubitemid 38720929)
44. Jang K. S., Song Y. S., Jang S. H., Min K. W., Na W., Jang S. M., Jun Y. J., Lee K. H., Choi D., Paik S. S., Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 2010 56 2 229 239 2-s2.0-73449138781 10.1111/j.1365-2559.2009.03468.x
45. Darido C., Georgy S. R., Wilanowski T., Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. Cancer Cell 2011 20 5 635 648
46. Garcia Pedrero J. M., Garcia Carracedo D., Muñoz Pinto C., Herrero Zapatero A., Rodrigo J. P., Suarez Nieto C., Gonzalez M. V., Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. International Journal of Cancer 2005 114 2 242 248 2-s2.0-13244265590 10.1002/ijc.20711 (Pubitemid 40194293)
47. Wang Y., Kristensen G. B., Helland A., Nesland J. M., Børresen-Dale A. L., Holm R., Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. American Journal of Clinical Pathology 2005 124 3 392 401 2-s2.0-24144486962 10.1309/BL7E-MW66-LQX6-GFRP (Pubitemid 41232925)
48. Tsao H., Mihm M. C., Sheehan C., PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. Journal of the American Academy of Dermatology 2003 49 5 865 872 2-s2.0-0142244844 10.1016/S0190-9622(03)02473-3 (Pubitemid 37314875)
49. Li L., Dutra A., Pak E., Ill J. E. L., Gerstein R. M., Pandolfi P. P., Recht L. D., Ross A. H., EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro-Oncology 2009 11 1 9 21 2-s2.0-61449191698 10.1215/15228517-2008-081
50. Yang J., Ren Y., Wang L., Li B., Chen Y., Zhao W., Xu W., Li T., Dai F., PTEN mutation spectrum in breast cancers and breast hyperplasia. Journal of Cancer Research and Clinical Oncology 2010 136 9 1303 1311 2-s2.0-77955483827 10.1007/s00432-010-0781-3
51. Schmitz M., Grignard G., Margue C., Dippel W., Capesius C., Mossong J., Nathan M., Giacchi S., Scheiden R., Kieffer N., Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. International Journal of Cancer 2007 120 6 1284 1292 2-s2.0-33846968797 10.1002/ijc.22359
52. Kennedy R. D., Chen C. C., Stuckert P., Archila E. M., De La Vega M. A., Moreau L. A., Shimamura A., D'Andrea A. D., Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. Journal of Clinical Investigation 2007 117 5 1440 1449 2-s2.0-34248184445 10.1172/JCI31245 (Pubitemid 46718432)
53. Fang N. Y., Greiner T. C., Weisenburger D. D., Chan W. C., Vose J. M., Smith L. M., Armitage J. O., Mayer R. A., Pike B. L., Collins F. S., Hacia J. G., Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2003 100 9 5372 5377 2-s2.0-0037627448 10.1073/pnas.0831102100 (Pubitemid 36542712)
54. Haidar M. A., Kantarjian H., Manshouri T., Chang C. Y., O'Brien S., Freireich E., Keating M., Albitar M., ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer 2000 88 5 1057 1062 (Pubitemid 30127666)
55. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M. S., Timmers C., Hejna J., Grompe M., D'Andrea A. D., Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Molecular Cell 2001 7 2 249 262 2-s2.0-0035105291 10.1016/S1097-2765(01)00173-3 (Pubitemid 32206493)
56. Jacquemont C., Taniguchi T., Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Research 2007 67 15 7395 7405 2-s2.0-34547628200 10.1158/0008-5472.CAN-07-1015 (Pubitemid 47206570)
57. Landais I., Hiddingh S., McCarroll M., Yang C., Sun A., Turker M. S., Snyder J. P., Hoatlin M. E., Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Molecular Cancer 2009 8, article 133 2-s2.0-74549187963 10.1186/1476-4598-8-133
58. Adams B. K., Cai J., Armstrong J., Herold M., Lu Y. J., Sun A., Snyder J. P., Liotta D. C., Jones D. P., Shoji M., EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anti-Cancer Drugs 2005 16 3 263 275 2-s2.0-20044389847 10.1097/00001813- 200503000-00005 (Pubitemid 40283941)
59. Adams B. K., Ferstl E. M., Davis M. C., Herold M., Kurtkaya S., Camalier R. F., Hollingshead M. G., Kaur G., Sausville E. A., Rickles F. R., Snyder J. P., Liotta D. C., Shoji M., Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorganic and Medicinal Chemistry 2004 12 14 3871 3883 2-s2.0-2942726181 10.1016/j.bmc.2004. 05.006 (Pubitemid 38798249)
60. Chen M. J., Dumitrache L. C., Wangsa D., Ma S. M., Padilla-Nash H., Ried T., Hasty P., Cisplatin depletes TREX2 and causes robertsonian translocations as seen in TREX2 knockout cells. Cancer Research 2007 67 19 9077 9083 2-s2.0-35148822715 10.1158/0008-5472.CAN-07-1146 (Pubitemid 47535892)
61. Pizem J., Popovic M., Cör A., Expression of Gli1 and PARP1 in medulloblastoma: an immunohistochemical study of 65 cases. Journal of Neuro-Oncology 2011 103 3 459 467 2-s2.0-79959803041 10.1007/s11060-010-0431-2
62. Barton V. N., Donson A. M., Kleinschmidt-DeMasters B. K., Gore L., Liu A. K., Foreman N. K., PARP1 expression in pediatric central nervous system tumors. Pediatric Blood and Cancer 2009 53 7 1227 1230 2-s2.0-70449719266 10.1002/pbc.22141
63. Domagala P., Huzarski T., Lubinski J., Gugala K., Domagala W., PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Research and Treatment 2011 127 3 861 869 2-s2.0-79955738892 10.1007/s10549-011-1441-2
64. Liu X., Lei M., Erikson R. L., Normal cells, but not cancer cells, survive severe Plk1 depletion. Molecular and Cellular Biology 2006 26 6 2093 2108 2-s2.0-33644767315 10.1128/MCB.26.6.2093-2108.2006 (Pubitemid 43346913)
65. Shekhar M. P. V., Lyakhovich A., Visscher D. W., Heng H., Kondrat N., Rad6 overexpression induces multinucleation, centrosome amplification, abnormal mitosis, aneuploidy, and transformation. Cancer Research 2002 62 7 2115 2124 2-s2.0-0036532135 (Pubitemid 34408460)
66. Bartkova J., Zemanova M., Bartek J., Expression of CDK7/CAK in normal and tumor cells of diverse histogenesis, cell-cycle position and differentiation. International Journal of Cancer 1996 66 6 732 737 (Pubitemid 26197939)
67. Bouwman P., Aly A., Escandell J. M., Pieterse M., Bartkova J., Van Der Gulden H., Hiddingh S., Thanasoula M., Kulkarni A., Yang Q., Haffty B. G., Tommiska J., Blomqvist C., Drapkin R., Adams D. J., Nevanlinna H., Bartek J., Tarsounas M., Ganesan S., Jonkers J., 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural and Molecular Biology 2010 17 6 688 695 2-s2.0-77953291328 10.1038/nsmb.1831
68. Shinmura K., Tao H., Goto M., Igarashi H., Taniguchi T., Maekawa M., Takezaki T., Sugimura H., Inactivating mutations of the human base excision repair gene NEIL1 in gastric cancer. Carcinogenesis 2004 25 12 2311 2317 2-s2.0-10344242928 10.1093/carcin/bgh267 (Pubitemid 39625170)
69. Hiramoto T., Nakanishi T., Sumiyoshi T., Fukuda T., Matsuura S., Tauchi H., Komatsu K., Shibasaki Y., Inui H., Watatani M., Yasutomi M., Sumii K., Kajiyama G., Kamada N., Miyagawa K., Kamiya K., Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. Oncogene 1999 18 22 3422 3426 2-s2.0-0033519693 10.1038/sj.onc.1202691 (Pubitemid 29286989)
70. McManus K. J., Barrett I. J., Nouhi Y., Hieter P., Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proceedings of the National Academy of Sciences of the United States of America 2009 106 9 3276 3281 2-s2.0-62549124623 10.1073/pnas.0813414106
71. Yang M. H., Chiang W. C., Chou T. Y., Chang S. Y., Chen P. M., Teng S. C., Wu K. J., Increased NBS1 expression is a marker of aggressive head and neck cancer and overexpression of NBS1 contributes to transformation. Clinical Cancer Research 2006 12 2 507 515 2-s2.0-31544465282 10.1158/1078-0432.CCR-05-1231 (Pubitemid 43166142)
72. Shibata T., Kokubu A., Miyamoto M., Sasajima Y., Yamazaki N., Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. American Journal of Pathology 2011 178 3 1395 1402 2-s2.0-79952769109 10.1016/j.ajpath.2010.12.011
73. Stankovic T., Stewart G. S., Fegan C., Biggs P., Last J., Byrd P. J., Keenan R. D., Moss P. A. H., Taylor A. M. R., Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. Blood 2002 99 1 300 309 2-s2.0-0036096157 10.1182/blood.V99.1.300 (Pubitemid 34532997)
74. Zhang P., Bhakta K. S., Puri P. L., Newbury R. O., Feramisco J. R., Wang J. Y., Association of ataxia telangiectasia mutated (ATM) gene mutation/deletion with rhabdomyosarcoma. Cancer Biology and Therapy 2003 2 1, article 2 87 91 2-s2.0-0037484552
75. Tommiska J., Bartkova J., Heinonen M., Hautala L., Kilpivaara O., Eerola H., Aittomäki K., Hofstetter B., Lukas J., Von Smitten K., Blomqvist C., Ristimäki A., Heikkilä P., Bartek J., Nevanlinna H., The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer. Oncogene 2008 27 17 2501 2506 2-s2.0-42049122030 10.1038/sj.onc.1210885 (Pubitemid 351521092)